Press Releases

 
Press Releases
  Date Title View
Dec 1, 2016
BERKELEY, CA -- (Marketwired) -- 12/01/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the company will hold a Research and Development (R&D) Day in New York City next week where it will showcase its immuno-oncology program. The event, which is for institutional investors, will be webcast live and can be found in the Inv...
Nov 30, 2016
BERKELEY, CA -- (Marketwired) -- 11/30/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it will present clinical data from a Phase 1/2 clinical trial evaluating its immuno-oncology product, SD-101, in patients with low-grade, B cell lymphoma. The poster presentation will be made at the 58th American Society of Hematology (...
Nov 14, 2016
BERKELEY, CA -- (Marketwired) -- 11/14/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its Biologics License Application (BLA) for HEPLISAV-B™ [Hepatitis B Vaccine, Recombinant (Adjuvanted)] for immunization ...
Nov 9, 2016
BERKELEY, CA -- (Marketwired) -- 11/09/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced the presentation of findings from an ongoing Phase 1b/2 study investigating SD-101, Dynavax's intratumoral TLR9 agonist, in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy. Early results investigating 13 patients with m...
Nov 7, 2016
BERKELEY, CA -- (Marketwired) -- 11/07/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the third quarter and nine months ended September 30, 2016. The Company had $109.6 million in cash, cash equivalents and marketable securities as of September 30, 2016, compared to $196.1 million at December 31...
Oct 27, 2016
BERKELEY, CA -- (Marketwired) -- 10/27/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it has entered into a note purchase agreement with one or more funds of Deerfield Management Company, L.P, pursuant to which Dynavax has agreed to sell, and Deerfield has agreed to purchase, $100 million principal amount of Dynavax's 1...
Oct 26, 2016
BERKELEY, CA -- (Marketwired) -- 10/26/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced sub-group results from HBV-23, the pivotal Phase 3 trial of its investigational hepatitis B vaccine HEPLISAV-B™ [Hepatitis B Vaccine, Recombinant (Adjuvanted)]. The new subgroup analysis demonstrated that HEPLISAV-B, when administere...
Oct 9, 2016
BERKELEY, CA -- (Marketwired) -- 10/09/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced the first presentation of findings from an ongoing Phase 1/2 study evaluating SD-101, Dynavax's intratumoral TLR9 agonist, in combination with Keytruda ® (pembrolizumab), Merck's anti-PD-1 treatment. Early results evaluating five patients wi...
Sep 4, 2016
BERKELEY, CA -- (Marketwired) -- 09/04/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that the U.S. Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research has cancelled the scheduled November 16, 2016, Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting to review the Biolog...
Aug 5, 2016
BERKELEY, CA -- (Marketwired) -- 08/05/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the second quarter and six months ended June 30, 2016. The Company had $139.0 million in cash, cash equivalents and marketable securities as of June 30, 2016, compared to $196.1 million at December 31, 2015. Th...
FirstPrevious
3
...
NextLast
= add release to Briefcase